Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape. Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively for Organophosphate and Carbamate Poisoning. Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology). - The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Organophosphate and Carbamate Poisoning Overview 6 Therapeutics Development 7 Pipeline Products for Organophosphate and Carbamate Poisoning - Overview 7 Pipeline Products for Organophosphate and Carbamate Poisoning - Comparative Analysis 8 Organophosphate and Carbamate Poisoning - Therapeutics under Development by Companies 9 Organophosphate and Carbamate Poisoning - Therapeutics under Investigation by Universities/Institutes 10 Organophosphate and Carbamate Poisoning - Pipeline Products Glance 11 Early Stage Products 11 Organophosphate and Carbamate Poisoning - Products under Development by Companies 12 Organophosphate and Carbamate Poisoning - Products under Investigation by Universities/Institutes 13 Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development 14 Countervail Corporation 14 Hager Biosciences, LLC 15 Organophosphate and Carbamate Poisoning - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 AM-132 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 galantamine - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PlantVax-1502-H-N - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 RS-194B - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule for Organophosphate Poisoning - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Organophosphate and Carbamate Poisoning - Discontinued Products 36 Organophosphate and Carbamate Poisoning - Product Development Milestones 37 Featured News & Press Releases 37 Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016 7 Number of Products under Development for Organophosphate and Carbamate Poisoning - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Products under Investigation by Universities/Institutes, H2 2016 13 Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corporation, H2 2016 14 Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences, LLC, H2 2016 15 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Stage and Target, H2 2016 18 Number of Products by Stage and Mechanism of Action H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Organophosphate and Carbamate Poisoning - Discontinued Products, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.